First Time Loading...

Rhythm Pharmaceuticals Inc
NASDAQ:RYTM

Watchlist Manager
Rhythm Pharmaceuticals Inc Logo
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Watchlist
Price: 41.79 USD 5.72%
Updated: Mar 28, 2024

Intrinsic Value

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencie... [ Read More ]

The intrinsic value of one RYTM stock under the Base Case scenario is 25.95 USD. Compared to the current market price of 41.79 USD, Rhythm Pharmaceuticals Inc is Overvalued by 38%.

Key Points:
RYTM Intrinsic Value
Base Case
25.95 USD
Overvaluation 38%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Rhythm Pharmaceuticals Inc

Backtest RYTM Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling RYTM stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Impressive Revenue Growth Amidst Clinical Progress
2023-Q4 Earnings Call

Impressive Revenue Growth Amidst Clinical Progress

The company reported a substantial revenue increase of 175% year-over-year, totaling $24.2 million in Q4, driving full-year revenue to $77.4 million. Despite a minor setback with a state Medicaid resulting in the loss of patient reimbursement, the firm continued to see consistent demand and prescription growth. Alongside this financial progress, promising clinical trials showed significant weight loss in pediatric patients treated with innovative therapies, with label expansion efforts underway in European markets. R&D and SG&A expenses rose in reflection of this clinical and commercial expansion.

Financials

Balance Sheet Decomposition
Rhythm Pharmaceuticals Inc

Current Assets 308.3m
Cash & Short-Term Investments 275.8m
Receivables 14.9m
Other Current Assets 17.6m
Non-Current Assets 24.5m
PP&E 2.1m
Intangibles 7m
Other Non-Current Assets 15.3m
Current Liabilities 55.2m
Accounts Payable 4.9m
Accrued Liabilities 39.6m
Other Current Liabilities 10.8m
Non-Current Liabilities 107.8m
Long-Term Debt 106.1m
Other Non-Current Liabilities 1.6m
Efficiency

Earnings Waterfall
Rhythm Pharmaceuticals Inc

Revenue
77.4m USD
Cost of Revenue
-9.3m USD
Gross Profit
68.1m USD
Operating Expenses
-252.5m USD
Operating Income
-184.4m USD
Other Expenses
-321k USD
Net Income
-184.7m USD

Free Cash Flow Analysis
Rhythm Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

RYTM Profitability Score
Profitability Due Diligence

Rhythm Pharmaceuticals Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROIC is Increasing
29/100
Profitability
Score

Rhythm Pharmaceuticals Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

RYTM Solvency Score
Solvency Due Diligence

Rhythm Pharmaceuticals Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Negative Net Debt
Low D/E
74/100
Solvency
Score

Rhythm Pharmaceuticals Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RYTM Price Targets Summary
Rhythm Pharmaceuticals Inc

Wall Street analysts forecast RYTM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RYTM is 60.07 USD with a low forecast of 49.49 USD and a high forecast of 84 USD.

Lowest
Price Target
49.49 USD
18% Upside
Average
Price Target
60.07 USD
44% Upside
Highest
Price Target
84 USD
101% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

RYTM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

RYTM Price
Rhythm Pharmaceuticals Inc

1M 1M
-6%
6M 6M
+81%
1Y 1Y
+143%
3Y 3Y
+106%
5Y 5Y
+40%
10Y 10Y
+39%
Annual Price Range
41.79
52w Low
15.81
52w High
52.44
Price Metrics
Average Annual Return 28.22%
Standard Deviation of Annual Returns 101.64%
Max Drawdown -92%
Shares Statistics
Market Capitalization 2.5B USD
Shares Outstanding 60 140 500
Percentage of Shares Shorted 24.04%

RYTM Return Decomposition
Main factors of price return

What is price return decomposition?

RYTM News

Other Videos

Company Profile

Rhythm Pharmaceuticals Inc Logo
Rhythm Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.5B USD

Dividend Yield

0%

Description

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The company is headquartered in Boston, Massachusetts and currently employs 140 full-time employees. The company went IPO on 2017-10-05. The firm is focused on developing treatment for genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger (hyperphagia). The Company’s lead product candidate, IMCIVREE (setmelanotide), is a potent melanocortin-4 receptor (MC4R). IMCIVREE is developed for the treatment of rare genetic diseases of obesity. The company is focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger. The company targets the MC4R pathway to develop therapeutics for rare genetic diseases of obesity, including proopiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl syndrome (BBS), Alstrom syndrome, POMC or LEPR heterozygous deficiency obesity, Smith-Magenis syndrome, steroid receptor coactivator 1 (SRC1) deficiency obesity, MC4R deficiency obesity and SH2B adapter protein 1 (SH2B1) deficiency obesity.

Contact

MASSACHUSETTS
Boston
222 Berkeley St Fl 12
+18572644280.0
http://www.rhythmtx.com

IPO

2017-10-05

Employees

140

Officers

Chairman, President & CEO
Dr. David P. Meeker M.D.
CFO & Treasurer
Mr. Hunter C. Smith M.B.A.
Chief Technical Officer
Mr. Joseph Shulman
Executive VP & Head of International
Mr. Yann Mazabraud
Executive VP & Head of North America
Ms. Jennifer Lee
Corporate Controller, Principal Accounting Officer & Executive Director
Mr. Christopher German
Show More
Head of Investor Relations & Corporate Communications
Mr. David Connolly
Senior VP & General Counsel
Mr. Jim Flaherty
Vice President of Sales & Marketing
Ms. Sarah Ryan
Chief Human Resources Officer
Ms. Pamela J. Cramer
Show Less

See Also

Discover More
What is the Intrinsic Value of one RYTM stock?

The intrinsic value of one RYTM stock under the Base Case scenario is 25.95 USD.

Is RYTM stock undervalued or overvalued?

Compared to the current market price of 41.79 USD, Rhythm Pharmaceuticals Inc is Overvalued by 38%.